Fulcrum Therapeutics, Inc. (FULC) Market Cap & Valuation Ratios
Fulcrum Therapeutics, Inc. (FULC) has a market cap of $280.8M, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FULCFulcrum Therapeutics, Inc.Follow FULC — free
—
Price chart with a free account
- Market cap
- 280.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| FULC | 0.3 | — | — | — | — | — | — | -44% |
| AVIR | 0.3 | — | 0.3 | — | — | — | — | -91% |
| ZURA | 0.3 | — | — | — | — | — | — | — |
| XFOR | 0.3 | — | 12.8 | — | — | -52% | — | -237% |
| ARCT | 0.3 | — | 3.0 | — | — | -76% | -348% | — |
| FATE | 0.3 | — | 15.3 | — | — | -23% | — | -78% |
| RCKT | 0.3 | — | — | — | — | — | — | -82% |
| OCGN | 0.3 | — | 51.3 | — | — | -4% | — | — |
| LRMR | 0.2 | — | — | — | — | — | — | -267% |
| VNDA | 0.2 | — | 0.9 | — | — | +6% | -86% | -65% |
| DRUG | 0.2 | — | — | — | — | +4943% | — | — |
| Median of these 10 | — | 7.9 | — | — | -14% | -217% | -87% |
.
Growth vs. price
each dot a company · hover or tap for valuesFulcrum Therapeutics, Inc. — questions
- What is Fulcrum Therapeutics, Inc.'s market cap?
- $280.8M.
Every figure on this page comes from Fulcrum Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.